实用医学杂志 ›› 2021, Vol. 37 ›› Issue (18): 2307-2311.doi: 10.3969/j.issn.1006⁃5725.2021.18.001

• 述评 •    下一篇

大环内酯类药物在慢性呼吸道疾病的长期使用——BTS指南带来的临床思考

李玥懋, 黄俊文, 赵海金   

  1. 南方医科大学南方医院呼吸与危重症医学科慢性气道疾病实验室(广州 510515)

  • 出版日期:2021-09-25 发布日期:2021-09-25
  • 通讯作者: 赵海金 E⁃mail:zhjin@smu.edu.cn
  • 基金资助:
    国家自然科学基金项目(编号:81770033,81900027 82070030);广东省科技计划项目(编号:2017B020226006);广州市科技计划项目(编号:201804010069 

Long term use of macrolides in adults with chronic respiratory disease⁃Clinical thinking brought by British Thoracic Society guideline

LI Yuemao,HUANG Junwen,ZHAO Haijin.    

  1. Laboratory of Chronic Airway Diseases Department of Respiratory and Critical Care Medicine,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China   

  • Online:2021-09-25 Published:2021-09-25
  • Contact: ZHAO Haijin E⁃mail:zhjin@smu.edu.cn

摘要:

近年来大环内酯类药物的抗菌外作用及免疫调节作用越来越受到重视,已经成为哮喘、慢 性阻塞性肺疾病(简称慢阻肺)和支气管扩张症(简称支扩)等慢性呼吸道疾病治疗的重要选择。然而,临床上哪些患者更可能从治疗中获益,如何结合指南更规范的使用大环内酯类药物,减少可能带来的副作用,这给临床管理带来重大挑战。因此,本文结合英国胸科协会(BTS)指南,重点论述大环内酯类药物在慢性呼吸道疾病患者应用的适应证、主要依据、注意事项及未来需要重点考虑的问题。

关键词:

大环内酯类药物, 慢性呼吸道疾病, 适应证, 长期使用, 展望

Abstract:

In recent years,there has been much more interest in a non⁃antimicrobial action and immuno⁃ modulatory effects of macrolides,which have become an important choice for the treatment of asthma,chronic obstructive pulmonary disease(COPD)and bronchiectasis. However,which patients are more likely to benefit from the treatment,how to use macrolide drugs more standardized in combination with the guidelines,and reduce the possible side effects,which poses a major challenge to clinical management. Therefore,combined with the British Thoracic Society(BTS)guidelines,this article focuses on the indications,selection basis and future issues of macrolides in patients with chronic respiratory diseases.

Key words:

macrolides, chronic respiratory diseases, indications, long term use, prospect